Chronic Obstructive Pulmonary Disease
Authors: Michael R. Littner
Journal: Annals of Internal Medicine (2011)

In the Clinic5 April 2011Chronic Obstructive Pulmonary DiseaseDeborah Cotton, MD, MPH, Darren Taichman, MD, PhD, Sankey Williams, MD, and Michael R. Littner, MDDeborah Cotton, MD, MPH, Darren Taichman, MD, PhD, Sankey Williams, MD, and Michael R. Littner, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-154-7-201104050-01004 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Chronic obstructive pulmonary disease (COPD) is a treatable, preventable, and partially reversible disease characterized by progressive airflow obstruction documented by spirometry; it is associated with an abnormal inflammatory response of the lungs to noxious particles or gases (1–4).Between 10% and 20% of COPD in the United States is estimated to be caused by occupational or other exposure to chemical vapors, irritants, and fumes. However, a recent review suggested that the percentage of patients with COPD who never smoked is 25% in the United States and may vary worldwide between about 15% (Japan) and 48% (South Africa), with higher rates ...References1. Global Initiative for Chronic Obstructive Lung Disease. Accessed at www.goldcopd.org on 4 December 2010. Google Scholar2. American Thoracic Society. COPD Guidelines. Accessed at www.copd-ats-ers.org/copddoc.pdf on 20 November 2010. Google Scholar3. Department of Veterans Affairs and Department of Defense. COPD Guidelines. Accessed at www.healthquality.va.gov/Chronic_Obstructive_Pulmonary_Disease_COPD.asp on 27 November 2010. Google Scholar4. National Institute of Clinical Excellence. Management of chronic obstructive pulmonary disease in adults in primary and secondary care. Accessed at http://guidance.nice.org.uk/CG101/Guidance/pdf/English on 26 November 2010. Google Scholar5. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009;374:733-43. [PMID: 19716966] Google Scholar6. Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet. 2006; 367:1216-9. [PMID: 16631861] Google Scholar7. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370:765-73. [PMID: 17765526] Google Scholar8. Eisner MD, Anthonisen N, Coultas D, et al. Committee on Nonsmoking COPD, Environmental and Occupational Health Assembly. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Resp Crit Care Med 2010;182:693-718, [PMID: 20802169] Google Scholar9. Chronic Obstructive Pulmonary Disease Prevalence and Mortality. Accessed at the United States Enviromental Protection Agency at http://cfpub.epa.gov/eroe/index.cfm?fuseaction=detail.viewInd&lv=list.listByAlpha&r=216638&subtop=381 on 4 December 2010. Google Scholar10. U.S. Preventive Services Task Force. Screening for Chronic Obstructive Pulmonary Disease Using Spirometry: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2008.148:535-43. [PMID: 18316746] Google Scholar11. Wilt TJ, Niewoehner D, Kim C, et al. Use of spirometry for case finding, diagnosis, and management of chronic obstructive pulmonary disease (COPD). Evid Rep Technol Assess (Summ). 2005:1-7. [PMID: 16238364] Google Scholar12. Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 2008;336:598-600. [PMID: 18326503] Google Scholar13. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005-12. [PMID: 14999112] Google Scholar14. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581-6. [PMID: 10377201] Google Scholar15. Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006; 25:745-55. [PMID: 16818116] Google Scholar16. Blanco I, Gimeno E, Munoz PA, et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med. 2010;181:270-8. [PMID: 19875684] Google Scholar17. Rietema H, Holverda S, Bogaard HJ, et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J. 2008;31:759-64. [PMID: 18094009] Google Scholar18. Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J. 2008;32:619-28. [PMID: 18448495] Google Scholar19. National Asthma Education and Prevention Program Expert Panel Report 3:Guidelines for the Diagnosis and Management of Asthma. Accessed at www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf on 24 December 2010. Google Scholar20. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272:1497-505. [PMID: 7966841] Google Scholar21. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142:233-9. [PMID: 15710956] Google Scholar22. Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2007;147:633-8. [PMID: 17975186] Google Scholar23. Calverley PM, Anderson JA, Celli B, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-89. [PMID: 17314337] Google Scholar24. Tashkin DP, Celli B, Senn S, et al. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med 2008;359:1543-54. [PMID: 18836213] Google Scholar25. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178:332-8. [PMID: 18511702] Google Scholar26. Troosters T, Celli B, Lystig T, et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J. 2010;36:65-73. [PMID:20185426] Google Scholar27. van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005;26:214-22. [PMID: 16055868] Google Scholar28. Aaron SD, Vandemheen KL, Fergusson D et al; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146:545-55. [PMID: 17310045] Google Scholar29. Puhan MA, Bachmann LM, Kleijnen J, et al. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med. 2009;7:2-15. [PMID: 19144173] Google Scholar30. Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med. 2008;102:1099-108. [PMID: 18614347] Google Scholar31. Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD. 2009;6:320-9. [PMID: 19863361] Google Scholar32. Lee TA, Wilke C, Joo M, Stroupe KT, et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2009;169:1403-10. [PMID:19667304] Google Scholar33. Singh S, Loke YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr Opin Pulm Med. 2010;16:118-22. [PMID: 19926996] Google Scholar34. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59:1102-6. [PMID: 20814406] Google Scholar35. Poole PJ, Chacko E, Wood-Baker RW, et al. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006:CD002733. [PMID: 16437444] Google Scholar36. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204. [PMID: 3492164] Google Scholar37. Sethi S. Infectious exacerbations of chronic bronchitis: diagnosis and management. J Antimicrob Chemother. 1999;43 Suppl A:97-105. [PMID: 10225579] Google Scholar38. McCrory DC, Brown C, Gelfand SE, et al. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest. 2001;119:1190-209. [PMID: 11296189] Google Scholar39. Quon BS, Gan WQ, Sin DD. Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis. Chest. 2008;133:756-66. [PMID: 18321904] Google Scholar40. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999;340:1941-7. [PMID: 10379017] Google Scholar41. Hurst JR, Vestbo J, Anzueto A, Locantore N, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128-38. [PMID: 2084324730] Google Scholar42. Sasaki T, Nakayama K, Yasuda H, et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. J Am Geriatr Soc. 2009;57:1453-7. [PMID: 19515110] Google Scholar43. Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010;11:10-22. [PMID: 20109213] Google Scholar44. Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178:1139-47. [PMID: 1872343744] Google Scholar45. Poole P, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2010 Feb 17;(2):CD001287. [PMID 20166060] Google Scholar46. Decramer M, Rutten-van Mölken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005;365:1552-60. [PMID:15866309] Google Scholar47. Salman GF, Mosier MC, Beasley BW, et al. Rehabilitation for patients with chronic obstructive pulmonary disease: meta-analysis of randomized controlled trials. J Gen Intern Med. 2003;18:213-21. [PMID: 12648254] Google Scholar48. Puhan MA, Scharplatz M, Troosters T, et al. Respiratory rehabilitation after acute exacerbation of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2009, Issue 1. Ar. No.:CD005305. DOI:10.1002/14651858. CD005305.pub2. [PMID: 19160250] Google Scholar49. Guyatt GH, Nonoyama M, Lacchetti C, et al. A randomized trial of strategies for assessing eligibility for long-term domiciliary oxygen therapy. Am J Respir Crit Care Med. 2005;172:573-80. [PMID: 15901604] Google Scholar50. Centers for Medicare & Medicaid Services. Evidence of medical necessity oxygen claims. Accessed at www.cms.hhs.gov/transmittals/downloads/r1742B3.pdf on 20 November 2010. Google Scholar51. Bradley JM, O'Neill B. Short-term ambulatory oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005:CD004356. [PMID: 16235359] Google Scholar52. Cranston JM, Crockett AJ, Moss JR, et al. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005:CD001744. [PMID: 16235285] Google Scholar53. Lewis CA, Fergusson W, Eaton T, et al. Isolated nocturnal desaturation in COPD: prevalence and impact on quality of life and sleep. Thorax. 2009;64:133-8. [PMID: 18390630] Google Scholar54. American College of Physicians. Preoperative pulmonary risk stratification for noncardiothoracic surgery: systematic review for the American College of Physicians. Ann Intern Med. 2006;144:581-95. [PMID: 16618956] Google Scholar55. Ferreira IM, Brooks D, Lacasse Y, et al. Nutritional supplementation for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005:CD000998. [PMID: 15846608] Google Scholar56. Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348:2059-73. [PMID: 12759479] Google Scholar57. Berger RL, DeCamp MM, Criner GJ, and Celli BR. Lung volume reduction therapies for advanced emphysema: an update. Chest. 2010;138:407-17. [PMID: 20682529] Google Scholar58. United Network for Organ Sharing. The organ procurement and transplantation network. Accessed at http://optn.transplant.hrsa.gov/ar2009/ on 20 November 2010. Google Scholar59. Heng D, Sharples LD, McNeil K, et al. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant. 1998;17:1255-63. [PMID: 9883768] Google Scholar60. 2010 PQRI Measures List. Accessed at https://www.cms.gov/PQRI/Downloads/2010_PQRI_MeasuresList_111309.pdf on 4 December 2010. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byStudy of relationship between nitrogen dioxide and chronic obstructive pulmonary disease in Bushehr, IranChronic obstructive pulmonary disease as a risk factor for suicide: A systematic review and meta-analysisMeta-ECATNets for Modelling and Analyzing Clinical PathwaysThe impact of exacerbation frequency on mortality following acute exacerbations of COPD: a registry-based cohort studyResponse to a Mobile Health Decision-Support System for Screening and Management of Tobacco UseHospitalization with acute exacerbation of chronic obstructive pulmonary disease and associated health resource utilization: A population-based Danish cohort studyCOPD (慢性閉塞性肺疾患) の診断と治療 5 April 2011Volume 154, Issue 7Page: ITC4-1KeywordsBronchodilatorsDyspneaExerciseLungsOxygenSpirometrySputum ePublished: 5 April 2011 Issue Published: 5 April 2011 Copyright & PermissionsCopyright © 2011 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...